Additionally, we have chosen not to focus on BCL2A1, a recently described melanoma oncogene and mediator of BRAF inhibitor resistance in a subset of melanomas, as this was the subject of an independent analysis in our program [34]. This evidence concerns the gene BCL2A1 and melanoma.